Incepta’s Vaccine Ambitions Bridled By Bangladesh Regulatory Gap
This article was originally published in PharmAsia News
Bangladesh's Incepta Vaccine is gearing up for a larger play with vaccines for pneumonia and human papillomavirus in the pipeline, but a non-functional national regulatory authority in the country could stymie its ambitions in terms of large-scale supplies of other products to Unicef, at least in the short-term.
You may also be interested in...
Vaccine specialist Hilleman announces partnership with another Indian firm, Bharat Biotech, to develop, manufacture and commercialize its simpler and cheaper oral cholera vaccine.
Bangladesh's Incepta group has launched its vaccine bulk manufacturing facility – a move that could have a significant impact on cost dynamics in a country that imports over 90 million doses of vaccines each year under its infant immunization plan. Incepta's chair Abdul Muktadir tells Scrip why this facility can make a difference and also outlines plans on the firm's tetravalent HPV vaccine.
White House directive aimed at reducing dependence on foreign manufacturers for essential medicines and a seemingly more aggressive stance towards site inspections could signal a worrying emerging trend for India pharma. But it also needs to be viewed through the prism of the upcoming US elections and trade tensions with China amid the pandemic.